Filing identity and reporting period
Important identity mismatch: The request identifies TAO Synergies Inc., but the supplied Form 10-K is for Synaptogenix, Inc. (Nasdaq: SNPX). The filing covers the fiscal year ended December 31, 2023, with 2022 as the comparable year; it is not a quarterly filing.
Synaptogenix is a development-stage biopharmaceutical company focused primarily on Bryostatin-1 for Alzheimer’s disease (AD), with other potential neurodegenerative and cognitive indications. It reported no operating revenue in either year.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Operating revenue | $0 | $0 |
| Research and development expense | $1.97 million | $6.32 million |
| General and administrative expense | $6.34 million | $9.81 million |
| Total operating expenses | $8.31 million | $16.13 million |
| Other income, net | $2.28 million | $10.56 million |
| Net loss | $6.04 million | $5.57 million |
| Net loss attributable to common stockholders | $13.78 million | $5.69 million |
| Basic and diluted loss per share | $1.18 | $0.81 |
| Cash used in operating activities | $5.17 million | $11.21 million |
The increase in net loss attributable to common stockholders reflects preferred-stock dividends and a $5.69 million deemed dividend associated with extinguishment accounting for the Series B preferred stock. The $2.28 million of other income included $1.65 million of interest income and changes in fair value of warrant and derivative liabilities; it is not operating revenue.
At December 31, 2023, cash and cash equivalents were $28.66 million, total current assets $30.53 million, current liabilities $4.28 million, working capital $26.26 million, total assets $31.11 million, and total liabilities $5.53 million. Cash was down from $37.48 million and working capital from $37.27 million at year-end 2022. The filing reports no conventional borrowings in the supplied financial statements, but Series B preferred-stock redemption and dividend obligations are significant financing commitments.
During 2023, the company redeemed $9.0 million of Series B preferred-stock principal and $1.02 million of accrued dividends through cash payments and share conversions. It issued 14.65 million common shares in installment conversions, plus 2.05 million shares related to deemed dividends. At year-end, $3.40 million of installment redemption payments remained accrued. Common shares outstanding rose from 7.27 million to 24.09 million during 2023.
Material changes versus 2022
- Operating expenses fell 48.5%, principally as the AD Phase 2 program wound down; R&D expense declined 68.8% and G&A declined 35.4%.
- Other income fell 78.5%, largely because gains from fair-value changes in warrant and derivative liabilities were much smaller than in 2022. Higher interest income partly offset the decline.
- Despite lower expenses, net loss increased 8.3%. Cash used in operations declined, while cash and working capital decreased.
- Common shares outstanding more than tripled, primarily reflecting Series B preferred-stock conversions and related issuances.
- The company made a $2.00 million investment in Cannasoul in 2023, comprising preferred shares and a convertible note; it purchased a further $500,000 milestone note in January 2024.
Outlook, development, risks and unusual items
- AD trial: The extended confirmatory Phase 2 study did not meet its primary endpoint. In March 2023, the company reported that nearly all pre-specified secondary endpoints in a severe AD subgroup (baseline MMSE-2 scores 10–14) were statistically significant, while the overall population and lower-severity stratum did not show statistically significant secondary results. The company said it was evaluating the data and determining next steps; these subgroup findings do not reverse the failed primary endpoint.
- Other programs: The Fragile X IND is on FDA clinical hold pending additional pharmacokinetic and pharmacodynamic analyses. A Cleveland Clinic Phase 1 MS study IND was filed in Q4 2023; enrollment depends on FDA approval. The company has not provided firm development milestones or financial guidance.
- Liquidity: Management said cash on hand was expected to fund projected requirements for at least 12 months from the filing date, including current development plans and potential preferred-stock redemptions. The filing also says additional capital or a strategic partner will be needed to pursue further clinical trials and potential approval; financing may be dilutive or unavailable on acceptable terms.
- Preferred-stock terms: Series B preferred stock carries a 7% annual dividend, compounded monthly, and certain triggering events may raise the rate to 15% and permit cash redemption at a premium. The company disclosed constraints on paying installments in shares and noted that its stock price was below the applicable floor price at filing.
- Listing and controls: Nasdaq granted an additional compliance period through April 22, 2024 to regain the $1.00 minimum bid-price requirement. Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to material weaknesses involving segregation of duties, period-end reporting processes, and IT general controls. No material misstatements were identified; the auditor did not attest to internal-control effectiveness.
- Other risks: The company has no product revenue and depends on financing, successful clinical development, third-party research and manufacturing, bryostatin supply, and continued rights under its CRE license. It reported no pending legal proceedings. The filing’s forward-looking statements are subject to substantial clinical, regulatory, financing, supply, dilution and market risks.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Synaptogenix, Inc., not TAO Synergies Inc.
- Review the full audited statements and notes, especially the Series B redemption schedule, cash-versus-share settlement terms, dividends, and subsequent payments.
- Reconcile the warrant-liability disclosures: the balance sheet and fair-value table show $140,000 at December 31, 2023, while a separate note passage states approximately $9.9 million for that date.
- Assess the complete AD trial data, subgroup analyses, and any subsequent FDA or management decisions; distinguish exploratory findings from the failed primary endpoint.
- Check current cash runway, financing needs, Nasdaq listing status, post-year-end share count, and progress in remediating the reported control weaknesses.